<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fludarabine is an effective treatment for follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL), but exposure to it negatively impacts stem cell mobilization and may increase the risk of subsequent <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We hypothesized that the risk that fludarabine imparts to stem cell mobilization and t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> would be affected by dose or timing </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with FL treated at Cleveland Clinic from 1991 to 2007 with autologous hematopoietic cell transplantation were evaluated </plain></SENT>
<SENT sid="3" pm="."><plain>Recursive partitioning analysis was used to explore associations of fludarabine and <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> dose and timing with poor stem cell harvest and t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We identified 171 patients, of whom 52 previously received fludarabine </plain></SENT>
<SENT sid="5" pm="."><plain>Patients exposed to fludarabine prior to auto-HCT were more likely to require &gt;5 days of leukapheresis (P&lt;0.001) and second stem cell mobilization (P&lt;0.001), especially at a cumulative dose &gt;150 mg/m(2) </plain></SENT>
<SENT sid="6" pm="."><plain>Univariable risk factors for t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> included the number of chemotherapy regimens before auto-HCT, the need for &gt;5 days of leukapheresis to collect CD34+ cells and fludarabine exposure in a dose-dependent manner, particularly when &gt;500 mg/m(2) </plain></SENT>
<SENT sid="7" pm="."><plain>A cumulative dose of fludarabine &gt;150 mg/m(2) increases the risk for poor stem cell harvests and any exposure increases the risk of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, with the greatest risk being at doses &gt;500 mg/m(2) </plain></SENT>
</text></document>